Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
US10071077B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Apr 14, 2015 |
| Grant date | Sep 11, 2018 |
| Priority date | — |
| Expiry date | Apr 14, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y301/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention involves the use of compounds from the class of aroyl-2H-imidazol-2-ones such as enoximone or a pharmaceutically acceptable salt thereof for modulating the immune system involved in a topic and immune-related disorders. In particular, the invention involves the use of (1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-on) or a pharmaceutically acceptable salt thereof. The invention also involves a pharmaceutical composition including aroyl-2H-imidazol-2-on or a pharmaceutically acceptable salt thereof in an active quantity for the treatment of a topic and immune-related disorders, by modulating the immune system involved in a topic and immune-related disorders. Preference is especially given to a pharmaceutical composition in a dosage unit of 5, 10 or 20 mg, based on the quantity of the active ingredient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.